Biphasic Catalytic Asymmetric Hydrogenation Process

双相催化不对称加氢工艺

基本信息

批准号：
7473883
负责人：
STEVEN D DIETZ
金额：
$ 37.77万
依托单位：
TDA RESEARCH, INC.
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-03-02 至 2010-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7473883
关键词：
Accounting Acids Alkanes Alkenes Amines Aspartame BINAP Back Blood Capital Carbapenems Carboxylic Acids Catalysis Characteristics Chemicals Class Complement Condition Development Disadvantaged Disease Drug Industry Economics Funding Gases Goals Heptanes High temperature of physical object Hydrogen Hydrogenation Ibuprofen Industry Isomerism Ketoprofen Laboratories Licensing Ligands Liquid substance Metals Methanol Methods Metric Modeling Naproxen Numbers Optics Pain Pharmaceutical Preparations Pharmacologic Substance Phase Phosphines Precipitation Procedures Process Product Recycling Production Productivity Rate Reaction Recycling Regulation Relative (related person)Research Resolution Rhodium Route Running Ruthenium Safety Savings Solubility Solutions Solvents Stream Structure System Techniques Technology Temperature Therapeutic Time United States Food and Drug Administration Vitamin E Work base catalyst chemical synthesis cost desire enantiomer feeding improved innovation interest phosphine prevent quality assurance reaction rate tiglic acid

项目摘要

DESCRIPTION (provided by applicant): A major change in pharmaceutical manufacturing is the current shift from batch to continuous processing. Manufacturing costs account for 36% of the industries costs and continuous processing can reduce operating expenses by at least 90% and capital expenses by at least 50%. The FDA and industry are working to bring continuous processing to pharmaceutical manufacturing. The use of enantioselective catalysts is another means to reduce costs. Homogeneous catalysts are able to produce chiral drugs and intermediates with very high enantioselectivity. Unfortunately, these processes suffer problems, it is very difficult to remove the expensive catalyst from the reaction mixture and the reactions used to make active ingredients in the pharmaceutical industry have typically been carried out as batch reactions. One of the most important classes of homogeneous chiral reactions is asymmetric hydrogenation, which is used to make a variety of active ingredients, including Vitamin E, Carbapenem, S-Oxafloxazin and Aspartame. The goal of this proposal is to develop an asymmetric hydrogenation process that allows the continual feed, reaction, separation and reuse of a chiral catalyst resulting in dramatic saving in process costs.

描述（由申请人提供）：药物制造的重大变化是当前从批处理到连续处理的转变。制造成本占行业成本的36％和持续处理可以将运营费用减少至少90％，而资本费用至少减少了50％。 FDA和行业正在努力为制药制造带来持续的处理。使用对映选择性催化剂是降低成本的另一种手段。均质催化剂能够以非常高的对映选择性产生手性药物和中间体。不幸的是，这些过程遇到了问题，从反应混合物中去除昂贵的催化剂非常困难，并且通常以批量反应进行了用于制造制药行业活性成分的反应。最重要的类别均质手性反应之一是不对称的氢化，该反应用于制造各种活性成分，包括维生素E，碳青霉烯，S-恶性霉素和阿斯巴甜。该提案的目的是开发一个不对称的氢化过程，该过程允许手性催化剂的持续饲料，反应，分离和再利用，从而巨大节省过程成本。